Anti-metastatic treatment in colorectal cancer: Targeting signaling pathways

Current Pharmaceutical Design

Volumn 19, Issue 5, 2013, Pages 841-863

  Lemos, Clara ^a   Sack, Ulrike ^a   Schmid, Felicitas ^a   Juneja, Manisha ^a   Stein, Ulrike ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Colorectal cancer; HGF Met pathway; Metastasis; Molecular therapeutics; Wnt catenin pathway

Indexed keywords

ANTIMETASTATIC AGENT; APC PROTEIN; B RAF KINASE; BC 21; BETA CATENIN; BEVACIZUMAB; CALVASCULIN; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; IRINOTECAN; K RAS PROTEIN; NICLOSAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PANITUMUMAB; PROTEIN P53; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; SMALL INTERFERING RNA; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; WNT PROTEIN;

APOPTOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE ARREST; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; EPITHELIAL MESENCHYMAL TRANSITION; GENE DELETION; GENE EXPRESSION; HUMAN; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TREATMENT RESPONSE;

EID: 84875092951     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804547277     Document Type: Review

References (291)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010; 127(12): 2893-917.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in europe in 2008. Eur J Cancer 2010; 46(4): 765-81.
3. Boyle P, Ferlay J. Cancer incidence and mortality in europe, 2004. Ann Oncol 2005; 16(3): 481-8.
4. Stein U, Schlag PM. Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 2007; 176: 61-80.
5. O'connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new american joint committee on cancer sixth edition staging. J Natl Cancer Inst 2004; 96(19): 1420-5.
6. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61(5): 759-67.
7. Fodde R, Smits R, Clevers H. Apc, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001; 1(1): 55-67.
8. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87(2): 159-70.
9. Jen J, Powell SM, Papadopoulos N, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994; 54(21): 5523-6.
10. Powell SM, Zilz N, Beazer-Barclay Y, et al. Apc mutations occur early during colorectal tumorigenesis. Nature 1992; 359(6392): 235-7.
11. Nagase H, Nakamura Y. Mutations of the apc (adenomatous polyposis coli) gene. Hum Mutat 1993; 2(6): 425-34.
12. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000; 18(9): 1967-79.
13. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361(25): 2449-60.
14. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7(12): 979-87.
15. Baker SJ, Preisinger AC, Jessup JM, et al. P53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50(23): 7717-22.
16. Hahn SA, Schutte M, Hoque AT, et al. Dpc4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271(5247): 350-3.
17. Miyaki M, Kuroki T. Role of smad4 (dpc4) inactivation in human cancer. Biochem Biophys Res Commun 2003; 306(4): 799-804.
18. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342(18): 1350-8.
19. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101(19): 1308-24.
20. Christofori G. New signals from the invasive front. Nature 2006; 441(7092): 444-50.
21. Fidler IJ. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3(6): 453-8.
22. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4(6): 448-56.
23. Bernards R, Weinberg RA. A progression puzzle. Nature 2002; 418(6900): 823.
24. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331(6024): 1559-64.
25. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119(6): 1420-8.
26. Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 2008; 14(6): 818-29.
27. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009; 139(5): 871-90.
28. Sipos F, Galamb O. Epithelial-to-mesenchymal and mesenchymalto-epithelial transitions in the colon. World J Gastroenterol 2012; 18(7): 601-8.
29. Arnold D, Seufferlein T. Targeted treatments in colorectal cancer: State of the art and future perspectives. Gut 2010; 59(6): 838-58.
30. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 Suppl 16): 15-8.
31. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407-24.
32. Ellis LM, Hicklin DJ. Vegf-targeted therapy: Mechanisms of antitumour activity. Nat Rev Cancer 2008; 8(8): 579-91.
33. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-42.
34. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase iii study. J Clin Oncol 2008; 26(12): 2013-9.
35. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (folfox4) for previously treated metastatic colorectal cancer: Results from the eastern cooperative oncology group study e3200. J Clin Oncol 2007; 25(12): 1539-44.
36. Harari PM, Allen GW, Bonner JA. Biology of interactions: Antiepidermal growth factor receptor agents. J Clin Oncol 2007; 25(26): 4057-65.
37. Nicholson RI, Gee JM, Harper ME. Egfr and cancer prognosis. Eur J Cancer 2001; 37 Suppl 4: S9-15.
38. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351(4): 337-45.
39. Jonker DJ, O'callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357(20): 2040-8.
40. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360(14): 1408-17.
41. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359(17): 1757-65.
42. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the firstline treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27(5): 663-71.
43. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28(7): 1254-61.
44. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25(13): 1658-64.
45. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase iii trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The prime study. J Clin Oncol 2010; 28(31): 4697-705.
46. Peeters M, Price TJ, Cervantes A, et al. Randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with folfiri alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28(31): 4706-13.
47. Amado RG, Wolf M, Peeters M, et al. Wild-type kras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(10): 1626-34.
48. Dunn EF, Iida M, Myers RA, et al. Dasatinib sensitizes kras mutant colorectal tumors to cetuximab. Oncogene 2011; 30(5): 561-74.
49. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. Hgf rescues colorectal cancer cells from egfr inhibition via met activation. Clin Cancer Res 2011; 17(3): 472-82.
50. Diaz Jr. LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted egfr blockade in colorectal cancers. Nature 2012; 486: 537-40.
51. Misale S, Yaeger R, Hobor S, et al. Emergence of kras mutations and acquired resistance to anti-egfr therapy in colorectal cancer. Nature 2012; 486: 532-6.
52. Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol 2007; 27(21): 7551-9.
53. Korinek V, Barker N, Moerer P, et al. Depletion of epithelial stemcell compartments in the small intestine of mice lacking tcf-4. Nat Genet 1998; 19(4): 379-83.
54. Kuhnert F, Davis CR, Wang HT, et al. Essential requirement for wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of dickkopf-1. Proc Natl Acad Sci USA 2004; 101(1): 266-71.
55. Zhao ZM, Reynolds AB, Gaucher EA. The evolutionary history of the catenin gene family during metazoan evolution. BMC Evol Biol 2011; 11: 198.
56. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127(3): 469-80.
57. Amit S, Hatzubai A, Birman Y, et al. Axin-mediated cki phosphorylation of beta-catenin at ser 45: A molecular switch for the wnt pathway. Genes Dev 2002; 16(9): 1066-76.
58. Wang Z, Vogelstein B, Kinzler KW. Phosphorylation of betacatenin at s33, s37, or t41 can occur in the absence of phosphorylation at t45 in colon cancer cells. Cancer Res 2003; 63(17): 5234-5.
59. Su Y, Fu C, Ishikawa S, et al. Apc is essential for targeting phosphorylated beta-catenin to the scfbeta-trcp ubiquitin ligase. Mol Cell 2008; 32(5): 652-61.
60. Roose J, Molenaar M, Peterson J, et al. The xenopus wnt effector xtcf-3 interacts with groucho-related transcriptional repressors. Nature 1998; 395(6702): 608-12.
61. Hsieh JC, Rattner A, Smallwood PM, Nathans J. Biochemical characterization of wnt-frizzled interactions using a soluble, biologically active vertebrate wnt protein. Proc Natl Acad Sci USA 1999; 96(7): 3546-51.
62. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. An ldlreceptor-related protein mediates wnt signalling in mice. Nature 2000; 407(6803): 535-8.
63. Tamai K, Semenov M, Kato Y, et al. Ldl-receptor-related proteins in wnt signal transduction. Nature 2000; 407(6803): 530-5.
64. Zeng X, Tamai K, Doble B, et al. A dual-kinase mechanism for wnt co-receptor phosphorylation and activation. Nature 2005; 438(7069): 873-7.
65. Davidson G, Wu W, Shen J, et al. Casein kinase 1 gamma couples wnt receptor activation to cytoplasmic signal transduction. Nature 2005; 438(7069): 867-72.
66. Lee E, Salic A, Kruger R, Heinrich R, Kirschner MW. The roles of apc and axin derived from experimental and theoretical analysis of the wnt pathway. PLoS Biol 2003; 1(1): E10.
67. Schwarz-Romond T, Metcalfe C, Bienz M. Dynamic recruitment of axin by dishevelled protein assemblies. J Cell Sci 2007; 120(Pt 14): 2402-12.
68. Daniels DL, Weis WI. Beta-catenin directly displaces groucho/tle repressors from tcf/lef in wnt-mediated transcription activation. Nat Struct Mol Biol 2005; 12(4): 364-71.
69. Molenaar M, Van De Wetering M, Oosterwegel M, et al. Xtcf-3 transcription factor mediates beta-catenin-induced axis formation in xenopus embryos. Cell 1996; 86(3): 391-9.
70. Behrens J, Von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor lef-1. Nature 1996; 382(6592): 638-42.
71. Mosimann C, Hausmann G, Basler K. Parafibromin/hyrax activates wnt/wg target gene transcription by direct association with betacatenin/ armadillo. Cell 2006; 125(2): 327-41.
72. Alves-Guerra MC, Ronchini C, Capobianco AJ. Mastermind-like 1 is a specific coactivator of beta-catenin transcription activation and is essential for colon carcinoma cell survival. Cancer Res 2007; 67(18): 8690-8.
73. Kramps T, Peter O, Brunner E, et al. Wnt/wingless signaling requires bcl9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-tcf complex. Cell 2002; 109(1): 47-60.
74. Kawano Y, Kypta R. Secreted antagonists of the wnt signalling pathway. J Cell Sci 2003; 116(Pt 13): 2627-34.
75. Niehrs C. Function and biological roles of the dickkopf family of wnt modulators. Oncogene 2006; 25(57): 7469-81.
76. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. Novel mechanism of wnt signalling inhibition mediated by dickkopf-1 interaction with lrp6/arrow. Nat Cell Biol 2001; 3(7): 683-6.
77. Mao B, Wu W, Li Y, et al. Ldl-receptor-related protein 6 is a receptor for dickkopf proteins. Nature 2001; 411(6835): 321-5.
78. Semenov MV, Tamai K, Brott BK, et al. Head inducer dickkopf-1 is a ligand for wnt coreceptor lrp6. Curr Biol 2001; 11(12): 951-61.
79. Mao B, Wu W, Davidson G, et al. Kremen proteins are dickkopf receptors that regulate wnt/beta-catenin signalling. Nature 2002; 417(6889): 664-7.
80. Gonzalez-Sancho JM, Aguilera O, Garcia JM, et al. The wnt antagonist dickkopf-1 gene is a downstream target of betacatenin/ tcf and is downregulated in human colon cancer. Oncogene 2005; 24(6): 1098-103.
81. Li L, Mao J, Sun L, Liu W, Wu D. Second cysteine-rich domain of dickkopf-2 activates canonical wnt signaling pathway via lrp-6 independently of dishevelled. J Biol Chem 2002; 277(8): 5977-81.
82. Uren A, Reichsman F, Anest V, et al. Secreted frizzled-related protein-1 binds directly to wingless and is a biphasic modulator of wnt signaling. J Biol Chem 2000; 275(6): 4374-82.
83. Jass JR. Wnt pathway may not be implicated in all routes to colorectal cancer. Gut 2007; 56(2): 309; author reply-10.
84. Jin LH, Shao QJ, Luo W, et al. Detection of point mutations of the axin1 gene in colorectal cancers. Int J Cancer 2003; 107(5): 696-9.
85. Liu W, Dong X, Mai M, et al. Mutations in axin2 cause colorectal cancer with defective mismatch repair by activating betacatenin/ tcf signalling. Nat Genet 2000; 26(2): 146-7.
86. Miyoshi Y, Ando H, Nagase H, et al. Germ-line mutations of the apc gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci USA 1992; 89(10): 4452-6.
87. Nagase H, Miyoshi Y, Horii A, et al. Screening for germ-line mutations in familial adenomatous polyposis patients: 61 new patients and a summary of 150 unrelated patients. Hum Mutat 1992; 1(6): 467-73.
88. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010; 138(6): 2044-58.
89. Lamlum H, Papadopoulou A, Ilyas M, et al. Apc mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci USA 2000; 97(5): 2225-8.
90. Albuquerque C, Baltazar C, Filipe B, et al. Colorectal cancers show distinct mutation spectra in members of the canonical wnt signaling pathway according to their anatomical location and type of genetic instability. Genes Chromosomes Cancer 2010; 49(8): 746-59.
91. Johnson V, Volikos E, Halford SE, et al. Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut 2005; 54(2): 264-7.
92. Samowitz WS, Powers MD, Spirio LN, et al. Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res 1999; 59(7): 1442-4.
93. Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999; 59(14): 3346-51.
94. Shimizu Y, Ikeda S, Fujimori M, et al. Frequent alterations in the wnt signaling pathway in colorectal cancer with microsatellite instability. Genes Chromosomes Cancer 2002; 33(1): 73-81.
95. Webster MT, Rozycka M, Sara E, et al. Sequence variants of the axin gene in breast, colon, and other cancers: An analysis of mutations that interfere with gsk3 binding. Genes Chromosomes Cancer 2000; 28(4): 443-53.
96. Burgess AW, Faux MC, Layton MJ, Ramsay RG. Wnt signaling and colon tumorigenesis--a view from the periphery. Exp Cell Res 2011; 317(19): 2748-58.
97. Nathke I. Cytoskeleton out of the cupboard: Colon cancer and cytoskeletal changes induced by loss of apc. Nat Rev Cancer 2006; 6(12): 967-74.
98. Zumbrunn J, Kinoshita K, Hyman AA, Nathke IS. Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by gsk3 beta phosphorylation. Curr Biol 2001; 11(1): 44-9.
99. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of apc in vivo immediately perturbs wnt signaling, differentiation, and migration. Genes Dev 2004; 18(12): 1385-90.
100. Brabletz T, Jung A, Hermann K, et al. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 1998; 194(10): 701-4.
101. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene 2008; 27(55): 6920-9.
102. Dorudi S, Hanby AM, Poulsom R, Northover J, Hart IR. Level of expression of e-cadherin mrna in colorectal cancer correlates with clinical outcome. Br J Cancer 1995; 71(3): 614-6.
103. Karatzas G, Karayiannakis AJ, Syrigos KN, et al. E-cadherin expression correlates with tumor differentiation in colorectal cancer. Hepatogastroenterology 1999; 46(25): 232-5.
104. Mohri Y. Prognostic significance of e-cadherin expression in human colorectal cancer tissue. Surg Today 1997; 27(7): 606-12.
105. Truant SC, Gouyer VP, Leteurtre EA, et al. E-cadherin and betacatenin mrna levels throughout colon cancer progression. J Surg Res 2008; 150(2): 212-8.
106. Kuphal F, Behrens J. E-cadherin modulates wnt-dependent transcription in colorectal cancer cells but does not alter wntindependent gene expression in fibroblasts. Exp Cell Res 2006; 312(4): 457-67.
107. Aguilera O, Fraga MF, Ballestar E, et al. Epigenetic inactivation of the wnt antagonist dickkopf-1 (dkk-1) gene in human colorectal cancer. Oncogene 2006; 25(29): 4116-21.
108. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31(2): 141-9.
109. Caldwell GM, Jones C, Gensberg K, et al. The wnt antagonist sfrp1 in colorectal tumorigenesis. Cancer Res 2004; 64(3): 883-8.
110. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of sfrp genes allows constitutive wnt signaling in colorectal cancer. Nat Genet 2004; 36(4): 417-22.
111. Stein U, Arlt F, Walther W, et al. The metastasis-associated gene s100a4 is a novel target of beta-catenin/t-cell factor signaling in colon cancer. Gastroenterology 2006; 131(5): 1486-500.
112. Garrett SC, Varney KM, Weber DJ, Bresnick AR. S100a4, a mediator of metastasis. J Biol Chem 2006; 281(2): 677-80.
113. Sack U, Stein U. Wnt up your mind-intervention strategies for s100a4-induced metastasis in colon cancer. Gen Physiol Biophys 2009; 28(Focus Issue): F55-F64.
114. Hemandas AK, Salto-Tellez M, Maricar SH, Leong AF, Leow CK. Metastasis-associated protein s100a4--a potential prognostic marker for colorectal cancer. J Surg Oncol 2006; 93(6): 498-503.
115. Gongoll S, Peters G, Mengel M, et al. Prognostic significance of calcium-binding protein s100a4 in colorectal cancer. Gastroenterology 2002; 123(5): 1478-84.
116. Scholer-Dahirel A, Schlabach MR, Loo A, et al. Maintenance of adenomatous polyposis coli (apc)-mutant colorectal cancer is dependent on wnt/beta-catenin signaling. Proc Natl Acad Sci USA 2011; 108(41): 17135-40.
117. Barker N, Clevers H. Mining the wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5(12): 997-1014.
118. De Sousa EM, Vermeulen L, Richel D, Medema JP. Targeting wnt signaling in colon cancer stem cells. Clin Cancer Res 2011; 17(4): 647-53.
119. Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009; 5(2): 100-7.
120. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes wnt signalling. Nature 2009; 461(7264): 614-20.
121. Polakis P. Arming antibodies for cancer therapy. Curr Opin Pharmacol 2005; 5(4): 382-7.
122. He B, You L, Uematsu K, et al. A monoclonal antibody against wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004; 6(1): 7-14.
123. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering rnas directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003; 9(4): 1291-300.
124. Choi BR, Gwak J, Kwon HM, et al. Oligodeoxyribozymes that cleave beta-catenin messenger rna inhibit growth of colon cancer cells via reduction of beta-catenin response transcription. Mol Cancer Ther 2010; 9(6): 1894-902.
125. Anton R, Chatterjee SS, Simundza J, Cowin P, Dasgupta R. A systematic screen for micro-rnas regulating the canonical wnt pathway. PLoS One 2011; 6(10): e26257.
126. Kim NH, Kim HS, Kim NG, et al. P53 and microrna-34 are suppressors of canonical wnt signaling. Sci Signal 2011; 4(197): ra71.
127. Cha YH, Kim NH, Park C, et al. Mirna-34 intrinsically links p53 tumor suppressor and wnt signaling. Cell Cycle 2012; 11(7): 1273-81.
128. Su J, Zhang A, Shi Z, et al. Microrna-200a suppresses the wnt/beta-catenin signaling pathway by interacting with betacatenin. Int J Oncol 2012; 40(4): 1162-70.
129. Sun JY, Huang Y, Li JP, et al. Microrna-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin. Biochem Biophys Res Commun 2012; 420(4): 787-92.
130. Migliore C, Martin V, Leoni VP, et al. Mir-1 downregulation cooperates with macc1 in promoting met overexpression in human colon cancer. Clin Cancer Res 2012; 18(3): 737-47.
131. Clevers H. Colon cancer--understanding how nsaids work. N Engl J Med 2006; 354(7): 761-3.
132. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94(4): 252-66.
133. Dihlmann S, Von Knebel Doeberitz M. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005; 113(4): 515-24.
134. Moreira L, Castells A. Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets 2011; 12(13): 1888-94.
135. Husain SS, Szabo IL, Tamawski AS. Nsaid inhibition of gi cancer growth: Clinical implications and molecular mechanisms of action. Am J Gastroenterol 2002; 97(3): 542-53.
136. Chan TA. Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention. Curr Cancer Drug Targets 2003; 3(6): 455-63.
137. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal antiinflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol 2009; 10(5): 501-7.
138. Tuynman JB, Vermeulen L, Boon EM, et al. Cyclooxygenase-2 inhibition inhibits c-met kinase activity and wnt activity in colon cancer. Cancer Res 2008; 68(4): 1213-20.
139. Szabo E. Selecting targets for cancer prevention: Where do we go from here? Nat Rev Cancer 2006; 6(11): 867-74.
140. Meyskens FL, Jr., Mclaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008; 1(1): 32-8.
141. Sporn MB, Hong WK. Concomitant dfmo and sulindac chemoprevention of colorectal adenomas: A major clinical advance. Nat Clin Pract Oncol 2008; 5(11): 628-9.
142. Stein U, Arlt F, Smith J, et al. Intervening in beta-catenin signaling by sulindac inhibits s100a4-dependent colon cancer metastasis. Neoplasia 2011; 13(2): 131-44.
143. Sack U, Walther W, Scudiero D, et al. S100a4-induced cell motility and metastasis is restricted by the wnt/beta-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell 2011; 22(18): 3344-54.
144. Wong SC, Lo SF, Cheung MT, et al. Quantification of plasma beta-catenin mrna in colorectal cancer and adenoma patients. Clin Cancer Res 2004; 10(5): 1613-7.
145. Lepourcelet M, Chen YN, France DS, et al. Small-molecule antagonists of the oncogenic tcf/beta-catenin protein complex. Cancer Cell 2004; 5(1): 91-102.
146. Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of beta-catenin/creb-binding protein transcription [corrected]. Proc Natl Acad Sci USA 2004; 101(34): 12682-7.
147. Sack U, Walther W, Scudiero D, et al. Novel effect of antihelminthic niclosamide on s100a4-mediated metastatic progression in colon cancer. J Natl Cancer Inst 2011; 103(13): 1018-36.
148. Lu W, Lin C, Roberts MJ, et al. Niclosamide suppresses cancer cell growth by inducing wnt co-receptor lrp6 degradation and inhibiting the wnt/beta-catenin pathway. PLoS One 2011; 6(12): e29290.
149. Chen M, Wang J, Lu J, et al. The anti-helminthic niclosamide inhibits wnt/frizzled1 signaling. Biochemistry 2009; 48(43): 10267-74.
150. Osada T, Chen M, Yang XY, et al. Antihelminth compound niclosamide downregulates wnt signaling and elicits antitumor responses in tumors with activating apc mutations. Cancer Res 2011; 71(12): 4172-82.
151. Pan JX, Ding K, Wang CY. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer 2012.
152. Tian W, Han X, Yan M, et al. Structure-based discovery of a novel inhibitor targeting the beta-catenin/tcf4 interaction. Biochemistry 2012; 51(2): 724-31.
153. Woolf AS, Kolatsi-Joannou M, Hardman P, et al. Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros. J Cell Biol 1995; 128(1-2): 171-84.
154. Borowiak M, Garratt AN, Wustefeld T, et al. Met provides essential signals for liver regeneration. Proc Natl Acad Sci USA 2004; 101(29): 10608-13.
155. Huh CG, Factor VM, Sanchez A, et al. Hepatocyte growth factor/cmet signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004; 101(13): 4477-82.
156. Chmielowiec J, Borowiak M, Morkel M, et al. C-met is essential for wound healing in the skin. J Cell Biol 2007; 177(1): 151-62.
157. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995; 373(6516): 699-702.
158. Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995; 373(6516): 702-5.
159. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995; 376(6543): 768-71.
160. Maina F, Hilton MC, Ponzetto C, Davies AM, Klein R. Met receptor signaling is required for sensory nerve development and hgf promotes axonal growth and survival of sensory neurons. Genes Dev 1997; 11(24): 3341-50.
161. Jeffers M, Rong S, Woude GF. Hepatocyte growth factor/scatter factor-met signaling in tumorigenicity and invasion/metastasis. J Mol Med (Berl) 1996; 74(9): 505-13.
162. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-met receptor: A paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994; 127(6 Pt 2): 1783-7.
163. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W. Hepatocyte growth factor/scatter factor induces a variety of tissuespecific morphogenic programs in epithelial cells. J Cell Biol 1995; 131(6 Pt 1): 1573-86.
164. Bernier J, Chababi W, Pomerleau V, Saucier C. Oncogenic engagement of the met receptor is sufficient to evoke angiogenic, tumorigenic, and metastatic activities in rat intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2010; 299(3): G677-86.
165. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of nih 3t3 cells induced by methepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994; 91(11): 4731-5.
166. Jeffers M, Fiscella M, Webb CP, et al. The mutationally activated met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 1998; 95(24): 14417-22.
167. Naldini L, Vigna E, Narsimhan RP, et al. Hepatocyte growth factor (hgf) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-met. Oncogene 1991; 6(4): 501-4.
168. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251(4995): 802-4.
169. Naka D, Ishii T, Yoshiyama Y, et al. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J Biol Chem 1992; 267(28): 20114-9.
170. Stella MC, Comoglio PM. Hgf: A multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 1999; 31(12): 1357-62.
171. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the met receptor. EMBO J 1991; 10(10): 2867-78.
172. Gherardi E, Youles ME, Miguel RN, et al. Functional map and domain structure of met, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 2003; 100(21): 12039-44.
173. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77(2): 261-71.
174. Maina F, Casagranda F, Audero E, et al. Uncoupling of grb2 from the met receptor in vivo reveals complex roles in muscle development. Cell 1996; 87(3): 531-42.
175. Weidner KM, Di Cesare S, Sachs M, et al. Interaction between gab1 and the c-met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996; 384(6605): 173-6.
176. Lock LS, Royal I, Naujokas MA, Park M. Identification of an atypical grb2 carboxyl-terminal sh3 domain binding site in gab docking proteins reveals grb2-dependent and-independent recruitment of gab1 to receptor tyrosine kinases. J Biol Chem 2000; 275(40): 31536-45.
177. Pelicci G, Giordano S, Zhen Z, et al. The motogenic and mitogenic responses to hgf are amplified by the shc adaptor protein. Oncogene 1995; 10(8): 1631-8.
178. Boccaccio C, Ando M, Tamagnone L, et al. Induction of epithelial tubules by growth factor hgf depends on the stat pathway. Nature 1998; 391(6664): 285-8.
179. Sachs M, Weidner KM, Brinkmann V, et al. Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. J Cell Biol 1996; 133(5): 1095-107.
180. Ponzetto C, Zhen Z, Audero E, et al. Specific uncoupling of grb2 from the met receptor. Differential effects on transformation and motility. J Biol Chem 1996; 271(24): 14119-23.
181. Reddy KB, Krueger JS, Kondapaka SB, Diglio CA. Mitogenactivated protein kinase (mapk) regulates the expression of progelatinase b (mmp-9) in breast epithelial cells. Int J Cancer 1999; 82(2): 268-73.
182. Krueger JS, Keshamouni VG, Atanaskova N, Reddy KB. Temporal and quantitative regulation of mitogen-activated protein kinase (mapk) modulates cell motility and invasion. Oncogene 2001; 20(31): 4209-18.
183. Zeigler ME, Chi Y, Schmidt T, Varani J. Role of erk and jnk pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J Cell Physiol 1999; 180(2): 271-84.
184. Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE. Mapk/erk overrides the apoptotic signaling from fas, tnf, and trail receptors. J Biol Chem 2001; 276(19): 16484-90.
185. Rodrigues GA, Park M, Schlessinger J. Activation of the jnk pathway is essential for transformation by the met oncogene. EMBO J 1997; 16(10): 2634-45.
186. Chen HC, Chan PC, Tang MJ, Cheng CH, Chang TJ. Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation. J Biol Chem 1998; 273(40): 25777-82.
187. Beviglia L, Kramer RH. Hgf induces fak activation and integrinmediated adhesion in mtln3 breast carcinoma cells. Int J Cancer 1999; 83(5): 640-9.
188. Jin L, Fuchs A, Schnitt SJ, et al. Expression of scatter factor and cmet receptor in benign and malignant breast tissue. Cancer 1997; 79(4): 749-60.
189. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human nonsmall-cell lung carcinomas. Br J Cancer 1996; 74(12): 1862-8.
190. Guirouilh J, Le Bail B, Boussarie L, et al. Expression of hepatocyte growth factor in human hepatocellular carcinoma. J Hepatol 2001; 34(1): 78-83.
191. Schoedel KE, Tyner VZ, Kim TH, Michalopoulos GK, Mars WM. Hgf, met, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. Mod Pathol 2003; 16(1): 14-21.
192. Oh RR, Park JY, Lee JH, et al. Expression of hgf/sf and met protein is associated with genetic alterations of vhl gene in primary renal cell carcinomas. APMIS 2002; 110(3): 229-38.
193. Otte JM, Schmitz F, Kiehne K, et al. Functional expression of hgf and its receptor in human colorectal cancer. Digestion 2000; 61(4): 237-46.
194. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/hgf receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995; 1(2): 147-54.
195. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16(1): 68-73.
196. Weidner KM, Sachs M, Riethmacher D, Birchmeier W. Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-offunction mutations of the met receptor in epithelial cells. Proc Natl Acad Sci USA 1995; 92(7): 2597-601.
197. Neklason DW, Done MW, Sargent NR, et al. Activating mutation in met oncogene in familial colorectal cancer. BMC Cancer 2011; 11: 424.
198. Tyner JW, Fletcher LB, Wang EQ, et al. Met receptor sequence variants r970c and t992i lack transforming capacity. Cancer Res 2010; 70(15): 6233-7.
199. Umeki K, Shiota G, Kawasaki H. Clinical significance of c-met oncogene alterations in human colorectal cancer. Oncology 1999; 56(4): 314-21.
200. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3(4): 347-61.
201. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993; 90(5): 1937-41.
202. Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces wnt-independent nuclear translocation of betacatenin after met-beta-catenin dissociation in hepatocytes. Cancer Res 2002; 62(7): 2064-71.
203. Danilkovitch-Miagkova A, Miagkov A, Skeel A, et al. Oncogenic mutants of ron and met receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol 2001; 21(17): 5857-68.
204. Takeuchi H, Bilchik A, Saha S, et al. C-met expression level in primary colon cancer: A predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003; 9(4): 1480-8.
205. Kammula US, Kuntz EJ, Francone TD, et al. Molecular coexpression of the c-met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007; 248(2): 219-28.
206. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4(12): 915-25.
207. Stein U, Walther W, Arlt F, et al. Macc1, a newly identified key regulator of hgf-met signaling, predicts colon cancer metastasis. Nat Med 2009; 15(1): 59-67.
208. Migliore C, Petrelli A, Ghiso E, et al. Micrornas impair metmediated invasive growth. Cancer Res 2008; 68(24): 10128-36.
209. Kim S, Lee UJ, Kim MN, et al. Microrna mir-199a* regulates the met proto-oncogene and the downstream extracellular signalregulated kinase 2 (erk2). J Biol Chem 2008; 283(26): 18158-66.
210. Reid JF, Sokolova V, Zoni E, et al. Mirna profiling in colorectal cancer highlights mir-1 involvement in met-dependent proliferation. Mol Cancer Res 2012; 10(4): 504-15.
211. Parr C, Jiang WG. Hepatocyte growth factor activation inhibitors (hai-1 and hai-2) regulate hgf-induced invasion of human breast cancer cells. Int J Cancer 2006; 119(5): 1176-83.
212. Wu Y, Eigenbrot C, Liang WC, et al. Structural insight into distinct mechanisms of protease inhibition by antibodies. Proc Natl Acad Sci USA 2007; 104(50): 19784-9.
213. Gao CF, Xie Q, Zhang YW, et al. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor: C-met-driven models of leiomyosarcoma. Mol Cancer Ther 2009; 8(10): 2803-10.
214. Giordano S. Rilotumumab, a mab against human hepatocyte growth factor for the treatment of cancer. Curr Opin Mol Ther 2009; 11(4): 448-55.
215. Burgess TL, Sun J, Meyer S, et al. Biochemical characterization of amg 102: A neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther 2010; 9(2): 400-9.
216. Wen PY, Schiff D, Cloughesy TF, et al. A phase ii study evaluating the efficacy and safety of amg 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 2011; 13(4): 437-46.
217. Schoffski P, Garcia JA, Stadler WM, et al. A phase ii study of the efficacy and safety of amg 102 in patients with metastatic renal cell carcinoma. BJU Int 2011; 108(5): 679-86.
218. Underiner TL, Herbertz T, Miknyoczki SJ. Discovery of small molecule c-met inhibitors: Evolution and profiles of clinical candidates. Anticancer Agents Med Chem 2010; 10(1): 7-27.
219. Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006; 12(4): 1292-8.
220. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. Hgf/nk4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997; 420(1): 1-6.
221. Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Hepatic gene expression of nk4, an hgf-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 2004; 11(6): 419-30.
222. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12(20 Pt 1): 6144-52.
223. Jin H, Yang R, Zheng Z, et al. Metmab, the one-armed 5d5 anti-cmet antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68(11): 4360-8.
224. Surati M, Patel P, Peterson A, Salgia R. Role of metmab (oa-5d5) in c-met active lung malignancies. Expert Opin Biol Ther 2011; 11(12): 1655-62.
225. Tseng JR, Kang KW, Dandekar M, et al. Preclinical efficacy of the c-met inhibitor ce-355621 in a u87 mg mouse xenograft model evaluated by 18f-fdg small-animal pet. J Nucl Med 2008; 49(1): 129-34.
226. Petrelli A, Circosta P, Granziero L, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor downregulation and hampers biological activity. Proc Natl Acad Sci USA 2006; 103(13): 5090-5.
227. Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-meturokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000; 60(2): 342-9.
228. Xie Q, Gao CF, Shinomiya N, et al. Geldanamycins exquisitely inhibit hgf/sf-mediated tumor cell invasion. Oncogene 2005; 24(23): 3697-707.
229. Bagai R, Fan W, Ma PC. Arq-197, an oral small-molecule inhibitor of c-met for the treatment of solid tumors. IDrugs 2010; 13(6): 404-14.
230. Munshi N, Jeay S, Li Y, et al. Arq 197, a novel and selective inhibitor of the human c-met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010; 9(6): 1544-53.
231. Belalcazar A, Azana D, Perez CA, Raez LE, Santos ES. Targeting the met pathway in lung cancer. Expert Rev Anticancer Ther 2012; 12(4): 519-28.
232. Qi W, Cooke LS, Stejskal A, et al. Mp470, a novel receptor tyrosine kinase inhibitor, in combination with erlotinib inhibits the her family/pi3k/akt pathway and tumor growth in prostate cancer. BMC Cancer 2009; 9: 142.
233. Smolen GA, Sordella R, Muir B, et al. Amplification of met may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor pha-665752. Proc Natl Acad Sci USA 2006; 103(7): 2316-21.
234. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-met kinase inhibits c-met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003; 63(21): 7345-55.
235. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-met, pf-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67(9): 4408-17.
236. Curran MP. Crizotinib: In locally advanced or metastatic non-small cell lung cancer. Drugs 2012; 72(1): 99-107.
237. Ganesan R, Kolumam GA, Lin SJ, et al. Proteolytic activation of pro-macrophage-stimulating protein by hepsin. Mol Cancer Res 2011; 9(9): 1175-86.
238. Wang X, Le P, Liang C, et al. Potent and selective inhibitors of the met [hepatocyte growth factor/scatter factor (hgf/sf) receptor] tyrosine kinase block hgf/sf-induced tumor cell growth and invasion. Mol Cancer Ther 2003; 2(11): 1085-92.
239. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25(27): 3787-800.
240. Yakes FM, Chen J, Tan J, et al. Cabozantinib (xl184), a novel met and vegfr2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10(12): 2298-308.
241. Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: Focus on xl-184 (cabozantinib). Drugs Today (Barc) 2011; 47(11): 857-68.
242. Zillhardt M, Park SM, Romero IL, et al. Foretinib (gsk1363089), an orally available multikinase inhibitor of c-met and vegfr-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res 2011; 17(12): 4042-51.
243. Davies H, Bignell GR, Cox C, et al. Mutations of the braf gene in human cancer. Nature 2002; 417(6892): 949-54.
244. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2(7): 358-64.
245. Whittaker S, Kirk R, Hayward R, et al. Gatekeeper mutations mediate resistance to braf-targeted therapies. Sci Transl Med 2010; 2(35): 35ra41.
246. Wilhelm SM, Carter C, Tang L, et al. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099-109.
247. Mross K, Frost A, Steinbild S, et al. A phase i dose-escalation study of regorafenib (bay 73-4506), an inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012; 18(9): 2658-67.
248. Tseng JR, Stuart D, Aardalen K, et al. Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of raf265, a novel b-raf/vegfr-2 inhibitor. Neoplasia 2011; 13(3): 266-75.
249. Yang H, Higgins B, Kolinsky K, et al. Rg7204 (plx4032), a selective brafv600e inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010; 70(13): 5518-27.
250. Hong S, Han SB. Overcoming metastatic melanoma with braf inhibitors. Arch Pharm Res 2011; 34(5): 699-701.
251. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to braf(v600e) inhibition through feedback activation of egfr. Nature 2012; 483(7387): 100-3.
252. Seger R, Ahn NG, Posada J, et al. Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated a431 cells. J Biol Chem 1992; 267(20): 14373-81.
253. Belanger LF, Roy S, Tremblay M, et al. Mek2 is dispensable for mouse growth and development. Mol Cell Biol 2003; 23(14): 4778-87.
254. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human map kinase kinase 1 (mek1) and mek2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004; 11(12): 1192-7.
255. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92(17): 7686-9.
256. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351(Pt 1): 95-105.
257. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the map kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5(7): 810-6.
258. Lorusso PM, Adjei AA, Varterasian M, et al. Phase i and pharmacodynamic study of the oral mek inhibitor ci-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23(23): 5281-93.
259. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase ii study of the oral mek inhibitor, ci-1040, in patients with advanced nonsmall-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22(22): 4456-62.
260. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4(12): 937-47.
261. Lorusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase i pharmacokinetic and pharmacodynamic study of the oral mapk/erk kinase inhibitor pd-0325901 in patients with advanced cancers. Clin Cancer Res 2010; 16(6): 1924-37.
262. Haura EB, Ricart AD, Larson TG, et al. A phase ii study of pd-0325901, an oral mek inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16(8): 2450-7.
263. Davies BR, Logie A, Mckay JS, et al. Azd6244 (arry-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007; 6(8): 2209-19.
264. Haass NK, Sproesser K, Nguyen TK, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor azd6244 (arry-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008; 14(1): 230-9.
265. Adjei AA, Cohen RB, Franklin W, et al. Phase i pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogenactivated protein kinase kinase 1/2 inhibitor azd6244 (arry-142886) in patients with advanced cancers. J Clin Oncol 2008; 26(13): 2139-46.
266. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase ii efficacy and pharmacogenomic study of selumetinib (azd6244; arry-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 2012; 18(7): 2056-65.
267. Choo EF, Belvin M, Boggs J, et al. Preclinical disposition of gdc-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Drug Metab Dispos 2012; 40(5): 919-27.
268. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: Mutations in a signalling pathway. Nature 2005; 436(7052): 792.
269. Rychahou PG, Kang J, Gulhati P, et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA 2008; 105(51): 20315-20.
270. Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM. Targeted molecular therapy of the pi3k pathway: Therapeutic significance of pi3k subunit targeting in colorectal carcinoma. Ann Surg 2006; 243(6): 833-42; discussion 43-4.
271. Johnson SM, Gulhati P, Rampy BA, et al. Novel expression patterns of pi3k/akt/mtor signaling pathway components in colorectal cancer. J Am Coll Surg 2010; 210(5): 767-76, 76-8.
272. Bhagwat SV, Gokhale PC, Crew AP, et al. Preclinical characterization of osi-027, a potent and selective inhibitor of mtorc1 and mtorc2: Distinct from rapamycin. Mol Cancer Ther 2011; 10(8): 1394-406.
273. Chresta CM, Davies BR, Hickson I, et al. Azd8055 is a potent, selective, and orally bioavailable atp-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70(1): 288-98.
274. Roper J, Richardson MP, Wang WV, et al. The dual pi3k/mtor inhibitor nvp-bez235 induces tumor regression in a genetically engineered mouse model of pik3ca wild-type colorectal cancer. PLoS One 2011; 6(9): e25132.
275. Blaser B, Waselle L, Dormond-Meuwly A, et al. Antitumor activities of atp-competitive inhibitors of mtor in colon cancer cells. BMC Cancer 2012; 12: 86.
276. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2012; 11(1): 1-13.
277. Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine, an oral, anti-cancer agent and inhibitor of the akt pathway: Mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol 2012; 8(5): 623-33.
278. Bendell JC, Nemunaitis J, Vukelja SJ, et al. Randomized placebocontrolled phase ii trial of perifosine plus capecitabine as secondor third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 2011; 29(33): 4394-400.
279. Simi L, Pratesi N, Vignoli M, et al. High-resolution melting analysis for rapid detection of kras, braf, and pik3ca gene mutations in colorectal cancer. Am J Clin Pathol 2008; 130(2): 247-53.
280. De Bacco F, Luraghi P, Medico E, et al. Induction of met by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 2011; 103(8): 645-61.
281. Pan BS, Chan GK, Chenard M, et al. Mk-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-met receptor. Cancer Res 2010; 70(4): 1524-33.
282. Zou HY, Li Q, Lee JH, et al. Sensitivity of selected human tumor models to pf-04217903, a novel selective c-met kinase inhibitor. Mol Cancer Ther 2012; 11(4): 1036-47.
283. Awada A, Gil T, Whenham N, et al. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: Results of a phase 1 trial. J Clin Pharmacol 2011; 51(12): 1674-84.
284. Galal KM, Khaled Z, Mourad AM. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. Indian J Cancer 2011; 48(1): 47-54.
285. Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of braf inhibitor vemurafenib in preclinical models of braf-mutant colorectal cancer. Cancer Res 2012; 72(3): 779-89.
286. Hoeflich KP, Merchant M, Orr C, et al. Intermittent administration of mek inhibitor gdc-0973 plus pi3k inhibitor gdc-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 2012; 72(1): 210-9.
287. Holt SV, Logie A, Davies BR, et al. Enhanced apoptosis and tumor growth suppression elicited by combination of mek (selumetinib) and mtor kinase inhibitors (azd8055). Cancer Res 2012; 72(7): 1804-13.
288. Altomare I, Bendell JC, Bullock KE, et al. A phase ii trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist 2011; 16(8): 1131-7.
289. Markman B, Tabernero J, Krop I, et al. Phase i safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mtor inhibitor bgt226 in patients with advanced solid tumors. Ann Oncol 2012.
290. Bendell JC, Rodon J, Burris HA, et al. Phase i, dose-escalation study of bkm120, an oral pan-class i pi3k inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30(3): 282-90.
291. Yap TA, Yan L, Patnaik A, et al. First-in-man clinical trial of the oral pan-akt inhibitor mk-2206 in patients with advanced solid tumors. J Clin Oncol 2011; 29(35): 4688-95.